BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
VANCOUVER, BC / ACCESS Newswire / January 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is excited to announce a major milestone in its research and development journey. The company is transitioning its cutting-edge R&D activities to the Gen-Plus Contract Research and Development Organization (CRDO) in Munich, Germany, with operations scheduled to begin on March 1, 2025. This move underscores BioNxt's commitment to scientific innovation and advancing solutions for unmet medical needs.
The new laboratory facility provides BioNxt with access to cutting-edge technologies, an expanded 1,000-square-meter research environment, and strategic opportunities for scientific collaboration within Europe's biotech hub. The transition is expected to accelerate the company's ongoing projects, particularly in the areas of drug delivery systems, neurodegenerative disease therapeutics, and next-generation biomedical technologies.
BioNxt Relocates to Gen-Plus: Strategic Importance for Advanced R&D
By leveraging the advanced and innovative infrastructure of the Gen-Plus Laboratory, BioNxt aims to harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt to:
Enhance R&D Capabilities: With access to cutting-edge equipment and analytical tools, BioNxt is better positioned to develop innovative solutions and optimize its research outcomes.
Foster Collaborations: The Munich location enables proximity to leading research institutions, biotech firms, and academic experts, paving the way for impactful partnerships.
Accelerate Innovation: The advanced resources at Gen-Plus Laboratory allow BioNxt to streamline workflows and reduce the time to bring groundbreaking therapies to market.
"BioNxt's transition to Gen-Plus marks a pivotal moment for BioNxt," said Hugh Rogers, CEO of BioNxt Solutions Inc. "This transition is both strategic and timely, and unlocking new possibilities for added strength on IP with innovation and reinforcing our mission to deliver transformative therapies for patients worldwide. We are thrilled about the opportunities that this new chapter brings, providing Impact on Current and Future projects."
BioNxt's innovative projects, including the development of advanced drug delivery systems such as sublingual thin films, transdermal patches, and other targeted therapeutic platforms, stand to gain significant advantages from the advanced capabilities at the Gen-Plus Laboratory. This cutting-edge facility is poised to accelerate preclinical research timelines, enhance formulation accuracy, and streamline the development of next-generation therapeutics.
About Gen-Plus GmbH & Co. KG
Gen-Plus GmbH & Co. KG, headquartered in Munich, Germany, is a premier Contract Research and Development Organization (CRDO) with over 25 years of experience in pharmaceutical formulation and development. The company operates a 1,000-square-meter state-of-the-art laboratory equipped for handling high-potency active pharmaceutical ingredients and licensed for GMP-compliant production, including narcotics.
Gen-Plus specializes in developing solid and semi-solid dosage forms, transdermal patches, and oral thin films, offering end-to-end services from feasibility studies to clinical trial supply production. The company leverages advanced technologies such as hot-melt extrusion, drug printing, and amorphization of APIs to deliver comprehensive pharmaceutical solutions.
Committed to innovation, Gen-Plus collaborates with leading European research institutions and biotech companies to drive advancements in pharmaceutical solutions. The company's expertise and cutting-edge infrastructure make it a trusted partner in accelerating drug development and commercialization.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information is based on management's expectations, estimates, projections, and assumptions as of the date of this press release. It is subject to significant risks, uncertainties, and other factors that could cause actual results or events to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, general economic conditions, market conditions, regulatory risks, technological advancements, and other factors described in the Company's public disclosure filings.
Readers are cautioned not to place undue reliance on forward-looking information, as actual outcomes may differ significantly from those expressed or implied, due to various factors beyond the Company's control. The Company undertakes no obligation to update or revise any forward-looking information, except as required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New GA-ASI Gambit 6 UCAV Adds Air-To-Ground Operations for International CCA4.11.2025 16:00:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / The latest iteration of the innovative Gambit Series of unmanned combat air vehicles (UCAV) from General Atomics Aeronautical Systems, Inc. (GA-ASI) is Gambit 6, a collaborative combat aircraft (CCA) that adds air-to-ground operations to its already proven air-to-air capability. The multi-role platform is optimized for roles such as electronic warfare, suppression of enemy air defenses (SEAD), and deep precision strike, making it a versatile option for evolving defense needs. Air forces throughout the world are looking to air-to-ground-capable CCAs to enhance operational capabilities and address emerging threats in a denied environment. Gambit 6 is being developed to meet the corresponding need for adaptability, scalability, and mission-specific performance. "These are real threats, and they require real solutions," said GA-ASI President David R. Alexander. "The modular architecture and signature-reducing internal weapons bay
FiberCop and FMC GlobalSat/MTN Seal Strategic Partnership to Develop Hybrid Terrestrial-satellite Network Architectures in Italy4.11.2025 13:00:00 CET | Press release
The two companies have signed a strategic partnership aimed at offering high-speed connectivity across Italy, enabling high-performance backhaul and last-mile services by integrating satellite backhaul and fiber access in remote areas. ROME, ITALY AND FORT LAUDERDALE, FL / ACCESS Newswire / November 4, 2025 / FiberCop, the company running Italy's most advanced, extensive and widespread digital network infrastructure has signed a strategic partnership with FMC GlobalSat and its 100% owned subsidiary MTNSat "MTN", a world-class satellite network operator, to develop cutting-edge hybrid terrestrial-satellite solutions to deliver stable connectivity in remote areas across Italy. This agreement represents one of the first architectures of its kind developed worldwide over Low Earth Orbit (LEO) satellite networks. Altogether, both companies have successfully completed tests with hybrid network architectures that integrate LEO satellite services into terrestrial infrastructures, specifically
Sauce Labs Introduces Sauce AI for Insights: Purpose-Built AI Agents That Transform Software Quality Data Into Instant Engineering Intelligence3.11.2025 16:00:00 CET | Press release
Purpose-Built AI Agents Eliminate Hours of Manual Test Analysis, Accelerating Release Cycles and Empowering Engineering Teams to Ship High-Quality Applications with Unprecedented Speed and Confidence SAN FRANCISCO, CA / ACCESS Newswire / November 3, 2025 / Sauce Labs, the leading platform for continuous quality, today announced Sauce AI for Insights, a groundbreaking suite of AI-powered data and analytics capabilities that fundamentally transforms how engineering teams analyze, understand, and act on real-time test execution and runtime data to deliver quality releases at speed - while offering enterprise-grade rigorous security and compliance controls. As the industry's first AI agent purpose-built for software quality intelligence, Sauce AI for Insights converts one of the most critical bottlenecks in modern software development into a strategic advantage: the overwhelming volume of test data that slows decision-making and delays releases now accelerates developer productivity and en
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of FLSmidth Cement from FLSmidth & Co. A/S3.11.2025 16:00:00 CET | Press release
LOS ANGELES, CA / ACCESS Newswire / November 3, 2025 / Pacific Avenue Capital Partners ("Pacific Avenue"), a leading global private equity firm focused on corporate carve-outs and other complex situations in the middle market, today announced it has completed the acquisition of FLSmidth Cement A/S ("FLSmidth Cement" or "Company"), from FLSmidth & Co. A/S (CPH:FLS) ("FLSmidth"). With the completion of the transaction, FLSmidth Cement will operate under the new name Fuller Technologies ("Fuller"), marking the beginning of its next chapter as an independent, technology-driven leader serving the global cement sector. Fuller is a leading solutions provider for the cement production industry focused on providing aftermarket parts and services to as well as new and replacement equipment for cement plants around the globe. The Company has manufacturing locations in North America, Europe, and Asia, and its global installed base spans over 1,400 of the world's approximate 2,700 cement plants. Wi
Scam Encounters Every Four Days: Mexico's Financial Toll3.11.2025 13:00:00 CET | Press release
This study of 1,000 Mexican adults reveals that over three-quarters have encountered a scam, with an average of one scam encounter happening every four days, equating to 86 scam encounters on average per person per year in Mexico. THE HAGUE, NL / ACCESS Newswire / November 3, 2025 / Additionally, nearly 3/5 of Mexican adults claim to have experienced a scam in the last year, with each scam victim being scammed on average 1.8 times. With widespread financial losses Shopping scams (55%), investment scams (48%) and unexpected money scams (47%) are the most common types of scams in Mexico, with some having money stolen via email while others received kidnapping threats. Additionally, over 1/3 of Mexican adults claim to have lost money to scams in the last year. Wire or bank transfers (55%) and debitcard payments (21%) are the most common methods used by scammers to receive payment. Of those who have experienced being scammed, 2/3 have reported the scam to the payment service, and half of t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom